Perks of Conceivium Biotech partnership
PGT (Pre-Implantation Genetic Testing)
PGT-A
Pre-Implantation Genetic Testing for Aneuploidy. Using a Next Generation Sequencing platform to assess embryo biopsies for chromosomal abnormalities.
PGT-M
Pre-Implantation Genetic Testing for Monogenic Conditions. Using Next Generation Sequencing platform to assess embryo biopsies for hereditary variants from parental origin. Uses custom probes developed with the patients to achieve optimal accuracy and may reduce the need for additional family members.
PGT-SR
Pre-Implantation Genetic Testing for Structural Rearrangements. Using Next Generation Sequencing platform to assess embryo biopsies for inherited abnormal karyotypes. Work directly with Conceivium Biotech to assess your specific case.
ReproMAP
Repro (Microbiome Assessment Panel), using Next Generation Sequencing for metagenomic analysis of vaginal swabs, menstrual blood, and semen to assess the microbiome of the fertility couple. This test allows species level identification of microbes found in the provided samples to ensure high levels of Lactobacillus species in the uterine and vaginal microbiomes. This test allows us to accurately characterize microbes that may be normal in these environments that genus level identification would characterize as harmful.
FemaleMAP: Assesses vaginal swab and menstrual blood samples.
PartnerMAP: Assesses vaginal swab, menstrual blood and semen samples.
Reprommunity
Uses qPCR, flow cytometry and ELISA techniques to assess the immune profile of the fertility couple. This test assesses the immunogenetics and immune cell profiles of both partners to determine the optimal conditions for the couple to conceive. This test detects immune cell ratios, cytokine ratios, T cell response, immune compatibility, parental immune genotypes, and parental immunogenetic overlaps.
ReproDUO
Combines our ReproMAP (FemaleMAP) test with our Reprommunity to provide a snapshot of the couples’ microbiome and immune systems in one bundle.
FSH Receptor Test
Uses qPCR technology to determine a patient’s optimal response to FSH medications to help optimize response during medical stimulation and reduce the risk of low-response.
Genetic Metabolic Profile
FTO and MC4R Test Uses qPCR technology to determine the specific genotype of a patient to assess their genetic predisposition to metabolic challenges. This assess how your body can respond to and create hunger hormones.